Evaluation of Denosumab Efficacy after Bisphosphonate Use in Patients with Osteoporosis: A Single Center Experience

Özlem Doğan

  • Year : 2025
  • Vol : 41
  • Issue : 1
  •  Page : 1-6
ABSTRACT
Objective: Osteoporosis is a disease in which the bone mass and structure are weakened as a result of the decrease in the mineral density in the bones, and the bones become brittle. In addition to the use of adequate calcium and vitamin D in the treatment of osteoporosis, drugs that prevent bone resorption and increase bone formation are used. The aim of this study was to evaluate the efficacy and safety of denosumab after the use of bisphosphonates in the Turkish population with osteoporosis.
Materials and Methods: Patients diagnosed with osteoporosis and using denosumab between 2018-2022 were involved in the study. Demographic, clinical, bone mineral density, and treatment characteristics of the patients were recorded. The patient's bone mineral density values after denosumab were compared with the baseline values.
Results: Analysis of the study was performed with data from 55 patients. All patients involved in the study were female, and the median age was 69 (46-90). The most common cause of osteoporosis was postmenopausal (56.4%), and the most common cause among secondary causes was primary hyperparathyroidism (14.5%). Fourteen (25.5%) patients had a history of fracture. After denosumab treatment, a statistically significant decrease was detected in the phosphorus (p=0.022) and alkaline phosphatase (p<0.001) levels of the patients. Improvement was observed in BMD (gr/cm2) values of L1-L4 (from 0.887 to 0.933), femoral neck (from 0.693 to 0.727), and total hip (from 0.762 to 0.782) regions with denosumab treatment. Similarly, the patients’ BMD Z scores and T scores were improved. Also, the denosumabrelated adverse event was not observed.
Conclusions: In this study, treatment characteristics of osteoporosis patients were retrospectively examined. Denosumab was well tolerated in patients, and no serious treatment-related side effects were detected. After bisphosphonate use, denosumab was shown to be an effective and safe treatment option in the treatment of osteoporosis.
Keywords: Osteoporosis, bisphosphonate, denosumab
Cite this Article As : Dogan O. Evaluation of Denosumab Efficacy after Bisphosphonate Use in Patients with Osteoporosis: A Single Center Experience. Selcuk Med J 2025;41(1): 1-6

Download Citation: Endnote/Zotero/Mendeley (RIS) RIS File

Download Citation: BibTeX BibTeX File

Conflict of interest : The authors declare that they have no conflict of interest.
This article is published under the CC BY-NC 4.0 license.
Selcuk Medical Journal
2025, Vol. 41 (1)
ISSN: 1017-6616
E-ISSN: 2149-8059
Received : , Accepted : , Published Online :

References

  1. 1. Siris ES, Adler R, Bilezikian J, Bolognese M, Dawson-Hughes B, Favus MJ, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int. 2014;25(5):1439-43. doi:10.1007/s00198-014-2655-z
  2. 2. Bai JC, Gonzalez D, Mautalen C, Mazure R, Pedreira S, Vazquez H, et al. Long-term effect of gluten restriction on bone mineral density of patients with coeliac disease. Aliment Pharmacol Ther. 1997;11(1):157-64. doi:10.1046/j.1365-2036.1997.112283000.x
  3. 3. Kerstetter JE, Mitnick ME, Gundberg CM, Caseria DM, Ellison AF, Carpenter TO, et al. Changes in bone turnover in young women consuming different levels of dietary protein. J Clin Endocrinol Metab. 1999;84(3):1052-5. doi:10.1210/jcem.84.3.5552
  4. 4. Brooke-Wavell K, Skelton DA, Barker KL, Clark EM, De Biase S, Arnold S, et al. Strong, steady and straight: UK consensus statement on physical activity and exercise for osteoporosis. Br J Sports Med. 2022;56(15):837-46. doi:10.1136/bjsports-2021-104634
  5. 5. Nawrat-Szołtysik A, Miodońska Z, Zarzeczny R, Zając-Gawlak I, Opara J, Grzesińska A, et al. Osteoporosis in Polish Older Women: Risk Factors and Osteoporotic Fractures: A Cross–Sectional Study. International Journal of Environmental Research and Public Health. 2020;17(10):3725.
  6. 6. LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, et al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33(10):2049-102. doi:10.1007/s00198-021-05900-y
  7. 7. Oryan A, Sahvieh S. Effects of bisphosphonates on osteoporosis: Focus on zoledronate. Life Sci. 2021;264:118681. doi:10.1016/j.lfs.2020.118681
  8. 8. Matsumoto T, Endo I. RANKL as a target for the treatment of osteoporosis. J Bone Miner Metab. 2021;39(1):91-105. doi:10.1007/s00774-020-01153-7
  9. 9. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-65. doi:10.1056/NEJMoa0809493
  10. 10. Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24(1):153-61. doi:10.1359/jbmr.0809010
  11. 11. Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25(1):72-81. doi:10.1359/jbmr.090716
  12. 12. Leder BZ. An Essential Warning. J Bone Miner Res. 2018;33(2):188-9. doi:10.1002/jbmr.3359
  13. 13. Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, et al. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res. 2018;33(2):190-8. doi:10.1002/jbmr.3337
  14. 14. Tripto-Shkolnik L, Fund N, Rouach V, Chodick G, Shalev V, Goldshtein I. Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider. Bone. 2020;130:115150. doi:10.1016/j.bone.2019.115150
  15. 15. Cowan A, Jeyakumar N, McArthur E, Fleet JL, Kanagalingam T, Karp I, et al. Hypocalcemia Risk of Denosumab Across the Spectrum of Kidney Disease: A Population-Based Cohort Study. J Bone Miner Res. 2023;38(5):650-8. doi:10.1002/jbmr.4804
  16. 16. Everts-Graber J, Lehmann D, Burkard JP, Schaller B, Gahl B, Hauselmann H, et al. Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis. J Bone Miner Res. 2022;37(2):340-8. doi:10.1002/jbmr.4472
  17. 17. Adami S, Libanati C, Boonen S, Cummings SR, Ho PR, Wang A, et al. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J Bone Joint Surg Am. 2012;94(23):2113-9. doi:10.2106/JBJS.K.00774